We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+34.55%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$904M
AUM Growth
+$79.9M
Cap. Flow
-$24.2M
Cap. Flow %
-2.67%
Top 10 Hldgs %
68.62%
Holding
34
New
7
Increased
7
Reduced
9
Closed
5

Top Buys

1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$31.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$22.6M
3
TERN
Terns Pharmaceuticals
TERN
+$21.8M
4
IRON icon
Disc Medicine
IRON
+$18.7M
5
AKTS
Aktis Oncology
AKTS
+$18.7M

Top Sells

1
DNTH icon
Dianthus Therapeutics
DNTH
+$27.2M
2
CDTX
Cidara Therapeutics
CDTX
+$22.1M
3
RAPT
RAPT Therapeutics
RAPT
+$19.4M
4
TRVI icon
Trevi Therapeutics
TRVI
+$14.9M
5
PHVS icon
Pharvaris
PHVS
+$13.5M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.77B
$163M 18.08%
1,946,667
-470,000
-19% -$27.2M
COGT icon
2
Cogent Biosciences
COGT
$6.68B
$90.5M 10.01%
2,350,000
– –
ABVX
3
Abivax
ABVX
$11.9B
$75.4M 8.34%
677,000
-79,000
-10% -$9.35M
ALMS
4
Alumis Inc
ALMS
$3.65B
$62.4M 6.9%
2,830,700
+300,000
+12% +$7.5M
DFTX
5
Definium Therapeutics
DFTX
$5.88B
$46.1M 5.1%
2,440,000
+210,000
+9% +$3.56M
AVBP icon
6
ArriVent BioPharma
AVBP
$1.55B
$45.5M 5.03%
1,971,054
– –
TSHA icon
7
Taysha Gene Therapies
TSHA
$1.71B
$39.6M 4.38%
8,859,911
– –
KYMR icon
8
Kymera Therapeutics
KYMR
$9.52B
$35.4M 3.92%
425,000
-110,000
-21% -$8.71M
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$7.25B
$31.3M 3.46%
+338,900
New +$31.9M
BIOA
10
BioAge Labs
BIOA
$1.01B
$30.6M 3.38%
1,748,000
+150,000
+9% +$2.89M
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$29.8M 3.3%
750,000
– –
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
$29.2M 3.23%
1,450,000
+176,667
+14% +$2.85M
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.6B
$28.5M 3.15%
+490,000
New +$22.6M
TERN
14
DELISTED
Terns Pharmaceuticals
TERN
$27.9M 3.09%
+530,000
New +$21.8M
OCUL icon
15
Ocular Therapeutix
OCUL
$1.96B
$26.8M 2.97%
3,166,600
+543,000
+21% +$5.18M
PALI icon
16
Palisade Bio
PALI
$342M
$18M 1.99%
10,276,317
+708,419
+7% +$1.29M
TRVI icon
17
Trevi Therapeutics
TRVI
$2.71B
$17.7M 1.96%
1,485,000
-1,330,000
-47% -$14.9M
IRON icon
18
Disc Medicine
IRON
$2.91B
$17.3M 1.91%
+270,000
New +$18.7M
AKTS
19
Aktis Oncology
AKTS
$1.38B
$17.2M 1.9%
+960,847
New +$18.7M
CNTX icon
20
Context Therapeutics
CNTX
$55.1M
$13.8M 1.52%
+5,250,000
New +$12.3M
DTIL icon
21
Precision BioSciences
DTIL
$203M
$12.3M 1.36%
2,236,732
+318,737
+17% +$1.47M
DBVT
22
DBV Technologies
DBVT
$870M
$12M 1.33%
574,200
– –
UNCY icon
23
Unicycive Therapeutics
UNCY
$147M
$6.58M 0.73%
1,000,000
– –
BBOT
24
BridgeBio Oncology
BBOT
$686M
$6.44M 0.71%
719,000
-324,110
-31% -$3.48M
LXEO icon
25
Lexeo Therapeutics
LXEO
$368M
$6.31M 0.7%
1,100,000
-625,000
-36% -$4.43M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Octagon Capital Advisors held 34 positions worth $904M, up 9.7% from $824M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Octagon Capital Advisors's Q1 2026 filing shows 7 new, 7 increased, 9 reduced and 5 closed positions. Its largest new stake was Mirum Pharmaceuticals: 338,900 shares worth $31.3M. The largest sale was Dianthus Therapeutics, an estimated $27.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

  • Octagon Capital Advisors's largest Q1 2026 buy was Mirum Pharmaceuticals: 338,900 shares worth $31.3M.
  • Octagon Capital Advisors added most to Alumis Inc in Q1 2026, an estimated $7.5M increase.
  • Octagon Capital Advisors's biggest Q1 2026 reduction was Dianthus Therapeutics, cutting an estimated $27.2M.
  • Octagon Capital Advisors fully exited Cidara Therapeutics in Q1 2026, selling an estimated $22.1M.
  • Octagon Capital Advisors's ten largest holdings make up 69% of its $904M portfolio in Q1 2026.
  • Octagon Capital Advisors opened 7 new positions and closed 5 in Q1 2026.
  • Octagon Capital Advisors's portfolio value rose 9.7% quarter-over-quarter to $904M.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.